Drug Development

Articles

Scottish Enterprise has awarded £20 million (US$27 million) to Valneva Scotland to advance vaccine development.

Valneva Awarded R&D Funding by Scottish Enterprise for Vaccine Development

Alvea has begun preclinical testing of a scalable, shelf-stable DNA vaccine against SARS-CoV-2 variants.

Alvea to Develop New DNA Vaccine Against SARS-CoV-2 Variants

Moderna and Thermo Fisher Scientific have formed a collaboration to leverage dedicated commercial fill/finish manufacturing capacity in the US for mRNA vaccines and therapies.

Moderna and Thermo Fisher Scientific Form Long-Term Strategic Manufacturing Collaboration

Recipharm has strengthened its biologics manufacturing capabilities with the acquisition of both Vibalogics and Arranta Bio.

Recipharm Acquires Two Biologics CDMOs: Vibalogics and Arranta Bio

The turnkey facilities will promote scalable vaccine production for an end-to-end manufacturing network for mRNA-based vaccines in Africa.

BioNTech Plans to Build Modular mRNA Manufacturing Facilities in Africa

Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.

Thermo Fisher Scientific Invests $40 Million to Expand Bioprocessing Manufacturing Site

Meg Rivers is the former senior editor for 

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Podcasts

In this episode of the Drug Solutions Podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview Sean Tucker, PhD, chief scientific officer of Vaxart, on developing oral recombinant vaccines.

Drug Solutions Podcast: Developing Oral Recombinant Vaccines

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

PharmTech interviewed Sartorius about SUS innovations and trends.

 Single-Use Systems in Downstream Processes

The acquisition will include Rewrite’s DNA writing platform, expanding Intellia’s genome editing tools.

Intellia Therapeutics Acquires Rewrite Therapeutics

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Analytical approaches must keep pace to ensure the identity, safety, and efficacy of evolving mRNA candidates.

Formulation and Drug Delivery